<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>16</Volume>
				<Issue>9</Issue>
				<PubDate PubStatus="epublish">
					<Year>2015</Year>
					<Month>09</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>High Expression of Matrix Metalloproteinase-11 indicates Poor Prognosis in Human Cholangiocarcinoma</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>3697</FirstPage>
			<LastPage>3701</LastPage>
			<ELocationID EIdType="pii">30975</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Cholangiocarcinoma (CHCA) is serious public health problem in Thailand, especially in thenortheastern and northern regions. CHCA is known as one of the most aggressive malignant tumors associatedwith local invasion and a high rate of metastasis. A crucial step in the invasion process is the proteolytic degradationof the extracellular matrix (ECM) and basal membranes, for which several studies have shown a critical roleplayed by matrix metalloproteinase-11 (MMP-11). &lt;br/&gt;&lt;b&gt;Objective&lt;/b&gt;: This study aim to detect MMP-11 expression inCHCA specimens and any correlation with survival time. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: A retrospective analysis wasconducted of 30 patients with CHCA in Rajvithi hospital, who had undergone immunohistochemical stainingof MMP-11. Relationships between clinicopathological data and MMP-11 expression in CHCA specimens wereanalyzed by the χ2 test or Fisher’s exact test. The estimated survival and the survival differences were analyzedby the Kaplan-Meier method and the log-rank test, respectively. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: MMP-11 expression was found in 15specimens (50%). The overall mean survival time is 237.0 days (95% CI 135.4-338.5, SD 271.9). Specimens with apositive MMP-11 had an average survival time of 136.7 days (95%CI 50.3-223.1, SD 156.0). Survival differenceswas signficant for the positive and negative MMP-11(p=0.022), but not well differentiated tumor and moderateto poor differentiated tumor (p=0.755), CA19-9 level of &gt;1,000 and &lt;1,000 (p=0.488), and between advancedand non-advanced staging (p=0.388). &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: The positive MMP-11 expression indicates poor prognosisin CHCA specimens.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">cholangiocarcinoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">matrix metalloproteinase-11</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Expression</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prognosis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_30975_5d21fcda2f82dda676844d9b9e06bc24.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
